Rationing treatment on the NHS - Still a political issue

Journal of the Royal Society of Medicine

Volumn 96, Issue 8, 2003, Pages 372-373

  Mossialos, Elias ^a   McKee, Martin ^b  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SILDENAFIL;

COST; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG INDUSTRY; EDITORIAL; HEALTH CARE; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR;

EID: 0042622530     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.96.8.372     Document Type: Editorial

References (10)

1. [www.nice.org.uk] (accessed 6 June 2003)
2. Smith R. Stumbling into rationing. BMJ 1999;319:936
3. Beecham L. UK issues guidance to doctors on Viagra. BMJ 1999;318:279
4. Council Directive 89/105/EC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems. Offic J Europ Commun 1989; L 40, 11.2
5. Dyer C. Viagra guidance declared unlawful. BMJ 1999;318:1509
6. Maynard A, Bloor K. Regulating the pharmaceutical industry. BMJ 1997;315:200-1
7. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001;323:1300-3
8. England and Wales Court of Appeal. R (ex parte Pfizer Ltd) v. The Secretary of State for Health. Case C/2002/0860. 6 November 2002.
9. House of Commons Health Committee. National Institute for Clinicai Excellence. Second Report of Session 2001-2002. HC 515-1. London: Stationery Office, 2002
10. McKee M, Figueras J. Setting priorities - can Britain learn from Sweden? BMJ 1996;312:691-4